ALX ONCOLOGY HOLDINGS INC
ALXODrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
5wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How ALXO's past catalysts played out
Evorpacept (ALX148)
Gastric Cancer
Paclitaxel
Breast Cancer, Metastatic
evorpacept
Head and Neck Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Evorpacept (ALX148) | Phase 3 | Gastric Cancer | - | - |
Paclitaxel | Phase 2 | Breast Cancer, Metastatic | - | - |
evorpacept | Phase 2 | Head and Neck Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ALX ONCOLOGY HOLDINGS INC's drug pipeline?→
CatalystAlert tracks 3 drug candidates in ALX ONCOLOGY HOLDINGS INC's (ALXO) pipeline across Phase 3, Phase 2. Its lead program is Evorpacept (ALX148) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ALX ONCOLOGY HOLDINGS INC's next FDA catalyst?→
ALX ONCOLOGY HOLDINGS INC's (ALXO) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALXO biotech catalysts?→
Add ALXO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ALX ONCOLOGY HOLDINGS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.